Cargando…
Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management
Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction (DGBI). IBS significantly impacts the quality of life of patients. Since its pathogenesis is unclear and can be multifactorial, it highlights the need for new and improved pharmaceutical drugs that not only improve bowel sy...
Autores principales: | Herekar, Anam, Shimoga, Dhanush, Jehangir, Asad, Shahsavari, Dariush, Yan, Yun, Karunaratne, Tennekoon Buddhika, Sharma, Amol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257918/ https://www.ncbi.nlm.nih.gov/pubmed/37309470 http://dx.doi.org/10.2147/CEG.S384251 |
Ejemplares similares
-
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017) -
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020) -
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021) -
Prevalence and Clinical Characteristics of Dyssynergic Defecation and Slow Transit Constipation in Patients with Chronic Constipation
por: Tanner, Samuel, et al.
Publicado: (2021) -
Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy
por: Sharma, Amol, et al.
Publicado: (2019)